Law360 (September 11, 2019, 2:37 PM EDT) -- Just as the U.S. Food and Drug Administration promised in its 2019 compounding priorities statement, the FDA recently published a notice and proposed rule in the Federal Register related to bulk drug substances that can be compounded subject to the conditions of Section 503A and Section 503B of the Federal Food, Drug and Cosmetic Act.
On Sept. 5, the FDA published a proposed rule regarding its intent to amend its regulations to add five bulk drug substances that can be used in compounding under Section 503A and proposed excluding another 26 bulk drug substances from the 503A bulks list.
Specifically, the FDA...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!